• Ave. 31 No. 15802 between 158 y 190, Cubanacán, Playa, Havana. C.P. 11600, P.O. Box 6162
  • webmaster@cigb.edu.cu
  • (53) 7-2504101; (53) 7-2716022

Preguntas frecuentes

Is there the possibility of vaccinating convalescent subjects from covid-19?

A phase I / II clinical trial is currently underway with the Abdala vaccine (intramuscular administration) and the Mambisa...

How is the Mambisa vaccine candidate designed?

Mambisa is a formulation with two proteins, which are two antigens obtained through recombinant DNA techniques. Protein subunit vaccines...

Is the use of Abdala being evaluated in the pediatric population?

Vaccinating the Cuban pediatric population is an objective of our vaccines and for this we have been developing the...

What is the route of administration and the immunization schedule for the Abdala vaccine?

Abdala is administered intramuscularly in a short or accelerated schedule of three doses separated by 14-day intervals (0-14-28 days).

What is the effectiveness of the Abdala vaccine?

The Abdala vaccine effectiveness study is ongoing. This study involves collecting data from all the municipalities of Cuba, which...

Under what conditions is the effectiveness of a vaccine measured?

When a vaccine begins to be used massively, then you have to measure its effectiveness, which is measured in...

What is the effectiveness of Abdala?

The efficacy of Abdala (92.8%) is to prevent the symptomatic disease: covid-19. Vaccines prevent, in a percentage, that the...

What is measured in clinical studies?

In clinical studies, the effectiveness of a vaccine is measured. They are controlled studies, under slightly more ideal conditions....

What are the components of the Abdala vaccine?

Abdala is a subunit vaccine, developed for vaccination against the SARS-CoV-2 virus. As active pharmaceutical ingredient it contains the...